Neuropsychiatric symptoms and lifelong mental activities in cerebral amyloid angiopathy - a cross-sectional study.

Humans Female Male Aged Cross-Sectional Studies Cerebral Amyloid Angiopathy / diagnostic imaging Magnetic Resonance Imaging Neuropsychological Tests Middle Aged Cognitive Dysfunction / diagnostic imaging Prospective Studies Severity of Illness Index Aged, 80 and over

Alzheimer’s disease Cerebral amyloid angiopathy Depression Lifelong mental activities Magnetic resonance imaging Neuropsychiatric symptoms White matter hyperintensities

Journal

Alzheimer's research & therapy

ISSN: 1758-9193

Titre abrégé: Alzheimers Res Ther

Pays: England

ID NLM: 101511643

Informations de publication

Date de publication:
04 Sep 2024

Historique:

received: 23 04 2024

accepted: 25 06 2024

medline: 5 9 2024

pubmed: 5 9 2024

entrez: 5 9 2024

Statut: epublish

Résumé

While several studies in cerebral amyloid angiopathy (CAA) focus on cognitive function, data on neuropsychiatric symptoms (NPS) and lifelong mental activities in these patients are scarce. Since NPS are associated with functional impairment, faster cognitive decline and faster progression to death, replication studies in more diverse settings and samples are warranted. We prospectively recruited n = 69 CAA patients and n = 18 cognitively normal controls (NC). The number and severity of NPS were assessed using the Alzheimer's Disease (AD) Assessment Scale's (ADAS) noncognitive subscale. We applied different regression models exploring associations between NPS number or severity and group status (CAA vs. NC), CAA severity assessed with magnetic resonance imaging (MRI) or cognitive function (Mini-Mental State Examination (MMSE), ADAS cognitive subscale), adjusting for age, sex, years of education, arterial hypertension, AD pathology, and apolipoprotein E status. Mediation analyses were performed to test indirect effects of lifelong mental activities on CAA severity and NPS. Patients with CAA had 4.86 times (95% CI 2.20-10.73) more NPS and 3.56 units (95% CI 1.94-5.19) higher expected NPS severity than NC. Higher total CAA severity on MRI predicted 1.14 times (95% CI 1.01.-1.27) more NPS and 0.57 units (95% CI 0.19-0.95) higher expected NPS severity. More severe white matter hyperintensities were associated with 1.21 times more NPS (95% CI 1.05-1.39) and 0.63 units (95% CI 0.19-1.08) more severe NPS. NPS number (MMSE mean difference - 1.15, 95% CI -1.67 to -0.63; ADAS cognitive mean difference 1.91, 95% CI 1.26-2.56) and severity (MMSE - 0.55, 95% CI -0.80 to -0.30; ADAS cognitive mean difference 0.89, 95% CI 0.57-1.21) predicted lower cognitive function. Greater lifelong mental activities partially mediated the relationship between CAA severity and NPS (indirect effect 0.05, 95% CI 0.0007-0.13), and greater lifelong mental activities led to less pronounced CAA severity and thus to less NPS (indirect effect - 0.08, 95% CI -0.22 to -0.002). This study suggests that NPS are common in CAA, and that this relationship may be driven by CAA severity. Furthermore, NPS seem to be tied to lower cognitive function. However, lifelong mental activities might mitigate the impact of NPS in CAA.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

We prospectively recruited n = 69 CAA patients and n = 18 cognitively normal controls (NC). The number and severity of NPS were assessed using the Alzheimer's Disease (AD) Assessment Scale's (ADAS) noncognitive subscale. We applied different regression models exploring associations between NPS number or severity and group status (CAA vs. NC), CAA severity assessed with magnetic resonance imaging (MRI) or cognitive function (Mini-Mental State Examination (MMSE), ADAS cognitive subscale), adjusting for age, sex, years of education, arterial hypertension, AD pathology, and apolipoprotein E status. Mediation analyses were performed to test indirect effects of lifelong mental activities on CAA severity and NPS.

RESULTS RESULTS

Patients with CAA had 4.86 times (95% CI 2.20-10.73) more NPS and 3.56 units (95% CI 1.94-5.19) higher expected NPS severity than NC. Higher total CAA severity on MRI predicted 1.14 times (95% CI 1.01.-1.27) more NPS and 0.57 units (95% CI 0.19-0.95) higher expected NPS severity. More severe white matter hyperintensities were associated with 1.21 times more NPS (95% CI 1.05-1.39) and 0.63 units (95% CI 0.19-1.08) more severe NPS. NPS number (MMSE mean difference - 1.15, 95% CI -1.67 to -0.63; ADAS cognitive mean difference 1.91, 95% CI 1.26-2.56) and severity (MMSE - 0.55, 95% CI -0.80 to -0.30; ADAS cognitive mean difference 0.89, 95% CI 0.57-1.21) predicted lower cognitive function. Greater lifelong mental activities partially mediated the relationship between CAA severity and NPS (indirect effect 0.05, 95% CI 0.0007-0.13), and greater lifelong mental activities led to less pronounced CAA severity and thus to less NPS (indirect effect - 0.08, 95% CI -0.22 to -0.002).

DISCUSSION CONCLUSIONS

This study suggests that NPS are common in CAA, and that this relationship may be driven by CAA severity. Furthermore, NPS seem to be tied to lower cognitive function. However, lifelong mental activities might mitigate the impact of NPS in CAA.

Identifiants

DOI: 10.1186/s13195-024-01519-3 PMID: 39232823

pubmed: 39232823

doi: 10.1186/s13195-024-01519-3

pii: 10.1186/s13195-024-01519-3

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

196

Informations de copyright

Références

Li Q, Yang Y, Reis C, Tao T, Li W, Li X, Zhang JH. Cereb Small Vessel Disease Cell Transplantation. 2018;27(12):1711–22.

Chojdak-Lukasiewicz J, Dziadkowiak E, Zimny A, Paradowski B. Cerebral small Vessel Disease: a review. Adv Clin Exp Med. 2021;30(3):349–56.

pubmed: 33768739 doi: 10.17219/acem/131216

Smith EE, Charidimou A, Ayata C, Werring DJ, Greenberg SM. Cerebral amyloid angiopathy-related transient focal neurologic episodes. Neurology. 2021;97(5):231–8.

pubmed: 34016709 pmcid: 8356377 doi: 10.1212/WNL.0000000000012234

Charidimou A, Boulouis G, Frosch MP, Baron J-C, Pasi M, Albucher JF, Banerjee G, Barbato C, Bonneville F, Brandner S, Calviere L, Caparros F, Casolla B, Cordonnier C, Delisle M-B, Deramecourt V, Dichgans M, Gokcal E, Herms J, Hernandez-Guillamon M, Jäger HR, Jaunmuktane Z, Linn J, Martinez-Ramirez S, MartinezSaez E, Mawrin C, Montaner J, Moulin S, Olivot J-M, Piazza F, Puy L, Raposo N, Rodrigues MA, Roeber S, Romero JR, Samarasekera N, Schneider JA, Schreiber S, Schreiber F, Schwall C, Smith C, Szalardy L, Varlet P, Viguier A, Wardlaw JM, Warren A, Wollenweber FA, Zedde M, van Buchem MA, Gurol ME, Viswanathan A, Salman RA-S, Smith EE, Werring DJ, Greenberg SM. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21(8):714–25.

pubmed: 35841910 pmcid: 9389452 doi: 10.1016/S1474-4422(22)00208-3

Zhang CE, Wong SM, van de Haar HJ, Staals J, Jansen JF, Jeukens CR, Hofman PA, van Oostenbrugge RJ, Backes WH. Blood-brain barrier leakage is more widespread in patients with cerebral small Vessel Disease. Neurology. 2017;88(5):426–32.

pubmed: 28031395 doi: 10.1212/WNL.0000000000003556

Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dyamic whole-brain disease. Stroke Vasc Neurol. 2016;1(3):83–82.

pubmed: 28959468 pmcid: 5435198 doi: 10.1136/svn-2016-000035

Greenberg SM, Vernooij MW, Cordnonnier C, Viswanathan A, Al-Shahi Salman R, Warach S, Launer LJ, Van Buchem MA, Breteler MM. Microbleed Study G. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8(2):165–74.

pubmed: 19161908 pmcid: 3414436 doi: 10.1016/S1474-4422(09)70013-4

Soontornniyomkij V, Lynch MD, Mermash S, Pomakian J, Badkoobehi H, Clare R, Vinters HV. Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain Pathol. 2010;20(2):459–67.

pubmed: 19725828 doi: 10.1111/j.1750-3639.2009.00322.x

Salat DH, Smith EE, Tuch DS, Benner T, Pappu V, Schwab KM, Gurol ME, Rosas HD, Rosand J, Greenberg SM. White matter alterations in cebreral amyloid angiopathy measured by diffusion tensor imaging. Stroke. 2006;37(7):1759–64.

pubmed: 16763176 doi: 10.1161/01.STR.0000227328.86353.a7

Case NF, Charlton A, Zwiers A, Batool S, McCreary CR, Hogan DB, Ismail Z, Zerna C, Coutts SB, Frayne R, Goodyear B, Haffenden A, Smith EE. Cerebral amyloid angiopathy is associated with executive dysfunction and mild cognitive impairment. Stroke. 2016;47:2010–6.

pubmed: 27338926 doi: 10.1161/STROKEAHA.116.012999

Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, Agüera-Ortuz L, Sweet R, Miller D, Lyketsos CG. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimer’s Dement 2016; 95–202.

Gahr M, Connemann BJ, Schonfeldt-Lecouna C. Behavioral problems and personality change related to cerebral amyloid angiopathy. Psychiatr Prax. 2012;39:410–3.

pubmed: 22972409

Gleason A, Hayhow B, Emmanuel J, Gaillard F. Cerebral amyloid angiopathy presenting with neuropsychiatric symptoms. Aust N Z J Psychiatry. 2014;48:779–80.

pubmed: 24563197 doi: 10.1177/0004867414525843

Matta G, Velakoulis D, Gaillard F, McLean CA, Yerra R. Creutzfeldt-Jakob disease, cerebral amyloid angiopathy, and Abeta-related angiitis with neuropsychiatric manifestations. Aust N Z J Psychiatry. 2017;51:740–1.

pubmed: 28176535 doi: 10.1177/0004867416686695

Devanand DP, Lee S, Huey ED, Goldberg TE. Associations between neuropsychiatric symptoms and neuropathological symptoms and neuropathological diagnoses of Alzheimer Disease and related dementias. JAMA Psychiatry. 2022;79(4):359–67.

pubmed: 35171235 pmcid: 8851371 doi: 10.1001/jamapsychiatry.2021.4363

Smith EE, Crites S, Wang M, Charlton A, Zwiers A, Sekhon R, Sajobi T, Camicioli R, McCreary CR, Frayne R, Ismail Z. Cerebral amyloid angiopathy is Associated with Emotional Dysregulation, Impulse Dyscontrol, and apathy. J Am Heart Association. 2021;10:e022089.

doi: 10.1161/JAHA.121.022089

Chokesuwattanaskul A, Zotin MCZ, Schoemaker D, Sveikata L, Gurol E, Greenberg SM, Viswanathan A. Apathy in patients with cerebral amyloid angiopathy. A Multimodal Neuroimaging Study. Neurology. 2023;100(19):e2007–2016.

pubmed: 36941070 pmcid: 10186225 doi: 10.1212/WNL.0000000000207200

Scopelliti G, Casolla B, Boulouis G, Kuchcinski G, Moulin S, Leys D, Henon H, Cordonnier C, Pasi M. Long-term neuropsychiatric symptoms in spontaneous intracerebral haemorrhage survivors. J Neurol Neurosurg Psychiatry. 2022;93:232–7.

pubmed: 34728587 doi: 10.1136/jnnp-2021-327557

Kaushik K, de Kort AM, van Dort R, van der Zwet RGJ, Siegerink B, Voigt S, van Zwet EW, van der Plas MC, koemans EA, Rasing I, Kessels RPC, Middelkoop HAM, Schreuder FHBM, Klijn CJM, Verbeek MM, Terwindt GM, van Etten ES, Wermer MJH. Neuropsychiatric symptoms with focus on apathy and irritability in sporadic and hereditary cerebral amyloid angiopathy. Alzheimers Res Therapy. 2024;16:74.

doi: 10.1186/s13195-024-01445-4

Wadsworth LP, Lorius N, Donovan NJ, Locascio JJ, Rentz DM, Johnson KA, Sperling RA, Marshal GA. Neuropsychiatric symptoms and global functional impairment along the Alzheimer’s continuum. Dement Geriatr Cogn Disord. 2012;34:96–111.

pubmed: 22922821 doi: 10.1159/000342119

David ND, Lin F, Porsteinsson AP. Alzheimer’s Disease Neuroimaging I. trajectories of neuropsychiatric symptoms and cognitive decline in mild cognitive impairment. Am J Geriatr Psychiatry. 2016;24:70–80.

pubmed: 26525995 doi: 10.1016/j.jagp.2015.06.001

Peters ME, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, Lyketsos CG. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172:460–5.

pubmed: 25585033 pmcid: 4416978 doi: 10.1176/appi.ajp.2014.14040480

Karsazi H, Hatami J, Rostami R, Moghadamzadeh A. The lifetime of experiences Questionnaire: Psychometric properties and relationships with memory function in an Iranian Elderly Sample. Front Psychiatry. 2022;13:889177.

pubmed: 35586406 pmcid: 9108157 doi: 10.3389/fpsyt.2022.889177

Opdebeeck C, Quinn C, Nelis SM, Clare L. Is cognitive lifestyle associated with depressive thoughts and self-reported depressive symptoms in later life? Eur J Ageing. 2016;13:63–73.

pubmed: 27034645 doi: 10.1007/s10433-015-0359-7

Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, van Buchem MA, Bruckmann H, Greenberg SM. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010;74:1346–50.

pubmed: 20421578 pmcid: 2875936 doi: 10.1212/WNL.0b013e3181dad605

Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzmann DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Elliott C, Masliah E, Ryan L, Silverberg N. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14(4):535–62.

doi: 10.1016/j.jalz.2018.02.018

Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38.

pubmed: 23867200 pmcid: 3714437 doi: 10.1016/S1474-4422(13)70124-8

Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for reserach into small vessel disease – advances since 2013. Lancet Neurol. 2023;22(7):602–18.

pubmed: 37236211 doi: 10.1016/S1474-4422(23)00131-X

Pasi M, Sugita L, Xiong L, et al. Association of Cerebral Small Vessel Disease and Cognitive decline after Intracerebral Hemorrhage. Neurology. 2021;96(2):e182–92.

pubmed: 33067403 pmcid: 7905779 doi: 10.1212/WNL.0000000000011050

Gregoire SM, Chaudhary UJ, Brown MM, et al. The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology. 2009;73(21):1759–66.

pubmed: 19933977 doi: 10.1212/WNL.0b013e3181c34a7d

Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32(6):1318–22.

pubmed: 11387493 doi: 10.1161/01.STR.32.6.1318

Charidimou A, Boulois G, Roongpiboonsopit D, Auriel E, Pasi M, Haley K, van Etten ES, Martinez-Ramirez S, Ayres A, Vashkevich A, Schwab KM, Goldstein JN, Rosand J, Viswanathan A, Greenberg SM, Gurol ME. Cortical superficial siderosis multifocality in cerebral amyloid Angiopathy. Prospective Study Neurol. 2017;89:2128–35.

Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36(5):268–72.

pubmed: 8864706 doi: 10.1159/000117270

Charidimou A, Martinez-Ramirez S, Reijmer YD, et al. Total Magnetic Resonance Imaging Burden of Small Vessel Disease in cerebral amyloid angiopathy. An imaging-pathologic study of Concept Valdiation. JAMA Neurol. 2016;73(8):994–1001.

pubmed: 27366898 pmcid: 5283697 doi: 10.1001/jamaneurol.2016.0832

Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.

pubmed: 31497854 doi: 10.1093/eurheartj/ehz486

Last AR, Ference JD, Menzel ER. Hyperlipidemia: drugs for Cardiovascular Risk reduction in adults. Am Fam Physician. 2017;95(2):78–87.

pubmed: 28084704

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines. Hypertension. 2018;71(6):e13–115.

pubmed: 29133356

Schreiber S, Vogel J, Schwimmer HD, Marks SM, Schreiber F, Jagust W. Impact of lifestyle dimensions on brain pathology and cognition. Neurobiol Aging. 2016;40:164–72.

pubmed: 26973116 pmcid: 4792130 doi: 10.1016/j.neurobiolaging.2016.01.012

Folstein MF, Folstein SE, McHugh PR, Fanjang G. Mini-mental state examination: MMSE user’s guide. Odessa, FL: Psychology Assessment Resources; 2000.

Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.

pubmed: 8232972 doi: 10.1212/WNL.43.11.2412-a

Julayanont P, DeToledo JC. Validity of the clinical dementia rating Scale Sum of boxes in staging and detection of cognitive impairment in Mexican americans. J Geriatr Psychiatr Neurol. 2022;35(1):128–34.

doi: 10.1177/0891988720973755

Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141(11):1356–64.

pubmed: 6496779 doi: 10.1176/ajp.141.11.1356

Marin DB, Green CR, Schmeidler J, Harvey PD, Lawlor BA, Ryan TM, Aryan M, Davis KL, Mohs RC. Noncognitive disturbances in Alzheimer’s Disease: frequency, Longitudinal Course, and relationship to cognitive symptoms. J Am Geriatr Soc. 2015;45(11):1331–8.

doi: 10.1111/j.1532-5415.1997.tb02932.x

Shin C, Park MH, Lee S-H, Ko Y-H, Kim Y-K, Han K-M, Jeong H-G, Han C. Usefulness of the 15-item geriatric depression scale (GDS-15) for classifying minor and major depressive disorders among community-dwelling elders. J Affect Disord. 2019;259:370–5.

pubmed: 31470180 doi: 10.1016/j.jad.2019.08.053

Valenzuela MJ, Sachdev P. Assessment of complex mental activity across the lifespan: development of the lifetime of experiences Questionnaire (LEQ). Psychol Med. 2006;37(7):1015–25.

pubmed: 17112402 doi: 10.1017/S003329170600938X

Badescu SV, Tataru C, Kobylinska L, Georgescu EL, Zahiu DM, Zagrean AM, Zagrean L. The association between diabetes mellitus and depression. J Med Life. 2016;9(2):120–5.

pubmed: 27453739 pmcid: 4863499

Zhang Y, Chen Y, Ma L. Depression and cardiovascular disease in elderly: current understanding. J Clin Neurosci. 2018;47:1–5.

pubmed: 29066229 doi: 10.1016/j.jocn.2017.09.022

Bahrmann A, Bahrmann P, Kubiak T, Kopf D, Oster P, Sieber CC, Daniel WG. Diabetes and dementia. Z Gerontol Geriatr. 2012;45(1):17–22.

pubmed: 22278002 doi: 10.1007/s00391-011-0269-z

Chang N-T, Su T-C. Investigating the association between familial hypercholesterolemia and perceived depression. Atheroscl Suppl. 2019;36:31–6.

doi: 10.1016/j.atherosclerosissup.2019.01.007

Fluharty M, Taylor AE, Grabski M, Munafo MR. The association of cigarette smoking with depression and anxiety: a systematic review. Nicotine Tob Res. 2017;19(1):3–13.

pubmed: 27199385 doi: 10.1093/ntr/ntw140

Kutner MH. Applied Linear Statistical Models; McGraw-Hill Irwin: Boston, MA, USA, 2005: 410.

Rubin DB. Multiple imputation for nonresponse in surveys. New York, NY: Wiley; 1987.

doi: 10.1002/9780470316696

Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Välimäki T, Martikainen J, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer’s disease. Int Geriatr Psychiatry. 2011;26:473–82.

doi: 10.1002/gps.2550

Fischer CE, Ismail Z, Schweizer TA. Deulusions increase functional impairment in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33:393–9.

pubmed: 22814093 doi: 10.1159/000339954

Balestreri L, Grossberg A, Grossberg GT. Behavioral and psychological symptoms of dementia as a risk factor for nursing home placement. Int Psychogeriatr. 2000;12:59–62.

doi: 10.1017/S1041610200006773

Angelelli P, Paolucci S, Bivona U, Piccardi L, Ciurli P, Cantagallo A, Antonucci G, Fasotti L, Di Santantonio A, Grasso MG, Pizzamiglio L. Development of neuropsychiatric symptoms in poststroke patients: a cross-sectional study. Acta Psychiatr Scand. 2004;110(1):55–63.

pubmed: 15180780 doi: 10.1111/j.1600-0447.2004.00297.x

Paranthaman R, Baldwin RC. Treatment of psychiatric syndromes due to cerebrovascular disease. Int Rev Psychiatry. 2006;18(5):453–70.

pubmed: 17085364 doi: 10.1080/09540260600935462

van Agtmaal MJM, Houben A, Pouwer F, Stehouwer CDA, Schram MT. Association of microvascular dysfunction with late-life depression: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74:729–39.

pubmed: 28564681 pmcid: 5710252 doi: 10.1001/jamapsychiatry.2017.0984

Tubi MA, Feingold FW, Kothapalli D, Hare ET, King KS, Thompson PM, Braski MN. White matter hyperintensities and their relationship to cognition: effects of segmentation algorithm. NeuroImage. 2020;206:116327.

pubmed: 31682983 doi: 10.1016/j.neuroimage.2019.116327

Castello JP, Pasi M, Kubiszewski BA, Abramson JR, Charidimou A, Kourkoulis C, DiPucchio Z, Schwab K, Anderson CD, Gurol ME, Greenberg SM, Rosand J, Viswanathan A, Biffi A. Cerebral small Vessel Disease and Depression among Intracerebral Hemorrhage survivors. Stroke. 2022;53:523–31.

pubmed: 34587793 doi: 10.1161/STROKEAHA.121.035488

Scopelliti G, Casolla B, Boulouis G, Kuchcinski G, Moulin S, Leys D, Henon H, Cordonnier C, Pasi M. Long-term anxiety in spontaneous intracerebral hemorrhage survivors. Int J Stroke. 2022;17(10):1093–9.

pubmed: 35187993 doi: 10.1177/17474930221085443

De Kort AM, Kaushik K, Kuiperij HB, Jäkel L, et al. The relation of a cerebrospinal fluid profile associated with Alzheimer’s disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy. Alzheimer’s Reseach Therapy. 2024;16:99.

doi: 10.1186/s13195-024-01454-3

Koemans EA, Chhatwal JP, van Veluw SJ, van Etten ES, van Osch MJP, van Walderveen MAA, et al. Progression of cerebral amyloid angiopathy: a pathophysiological framework. Lancet Neurol. 2023;22(7):632–42.

pubmed: 37236210 doi: 10.1016/S1474-4422(23)00114-X

Li P, Stuart EA, Allison DB. Multiple imputation. A flexible Tool for handling Missing Data. JAMA. 2015;314(18):1966–7.

pubmed: 26547468 pmcid: 4638176 doi: 10.1001/jama.2015.15281